Aditxt, Inc. 10-K — AI Bull & Bear Analysis

The 10-K reveals a company at a binary crossroads. On one side is a bold strategic pivot toward a dual-engine model of diagnostics and therapeutics, supported by an aggressive capital raising strategy. On the other is a balance sheet characterized by technical defaults, severe cash burn, and a cap table burdened by preferred stock redemptions. The transition to bitXbio represents an attempt to institutionalize the brand and align it with its new scientific direction. Ultimately, the investment thesis hinges on the 2026 IND submission for ADI-100. If the company can successfully navigate its current liquidity crisis and maintain its Nasdaq listing, the clinical data could provide the necessary catalyst for a recovery. However, the margin for error is non-existent, as any further delays in funding or regulatory setbacks could trigger a collapse of the company's core intellectual property licenses.